![Bradycardia associated with antithymocyte globulin treatment of a pediatric patient with sickle cell disease: a case report and literature review | Hematology, Transfusion and Cell Therapy Bradycardia associated with antithymocyte globulin treatment of a pediatric patient with sickle cell disease: a case report and literature review | Hematology, Transfusion and Cell Therapy](https://static.elsevier.es/multimedia/25311379/0000004400000002/v1_202205140837/S2531137920312888/v1_202205140837/en/main.assets/gr1.jpeg)
Bradycardia associated with antithymocyte globulin treatment of a pediatric patient with sickle cell disease: a case report and literature review | Hematology, Transfusion and Cell Therapy
In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia | Haematologica
![Anti Thymocyte Globulin Drug at best price in Mumbai by Nexus Lifecare Private Limited | ID: 7255552697 Anti Thymocyte Globulin Drug at best price in Mumbai by Nexus Lifecare Private Limited | ID: 7255552697](http://5.imimg.com/data5/SELLER/Default/2023/12/371790955/BZ/WU/WX/2784482/anti-thymocyte-globulin-drug-250x250.jpg)
Anti Thymocyte Globulin Drug at best price in Mumbai by Nexus Lifecare Private Limited | ID: 7255552697
![Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapy - American Journal of Transplantation Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapy - American Journal of Transplantation](https://www.amjtransplant.org/cms/attachment/f82b03b2-cd54-4803-81f3-d1c0ac762f8f/ga1_lrg.jpg)
Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapy - American Journal of Transplantation
![Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes | BMJ Open Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/11/12/e053669/F1.medium.gif)
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes | BMJ Open
![Presumed Serum Sickness Following Thymoglobulin Treatment of Acute Cellular Rejection of a Cardiac Allograft | MDedge Dermatology Presumed Serum Sickness Following Thymoglobulin Treatment of Acute Cellular Rejection of a Cardiac Allograft | MDedge Dermatology](https://cdn.mdedge.com/files/s3fs-public/Image/September-2017/ct100003186_fig.png)
Presumed Serum Sickness Following Thymoglobulin Treatment of Acute Cellular Rejection of a Cardiac Allograft | MDedge Dermatology
![Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation - ScienceDirect Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253815307614-fx3.gif)